These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23225807)

  • 1. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
    Kim G; Jung EJ; Ryu CG; Hwang DY
    Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
    Hanke B; Riedel C; Lampert S; Happich K; Martus P; Parsch H; Himmler B; Hohenberger W; Hahn EG; Wein A
    Ann Oncol; 2001 Feb; 12(2):221-6. PubMed ID: 11300328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
    Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G
    Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
    Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
    Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
    Nagai Y; Beppu T; Sakamoto Y; Miyamoto Y; Hayashi H; Nitta H; Imai K; Masuda T; Okabe H; Hirashima K; Imamura Y; Baba Y; Chikamoto A; Baba H
    Anticancer Res; 2014 Oct; 34(10):5529-35. PubMed ID: 25275051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
    Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Fan FS; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Int J Colorectal Dis; 2001 Apr; 16(2):96-101. PubMed ID: 11355325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancers.
    Ychou M; Duffour J; Kramar A; Grenier J
    Oncol Rep; 1998; 5(5):1245-50. PubMed ID: 9683844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
    Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
    Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
    Nozawa H; Ishihara S; Kawai K; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Watanabe T
    Oncology; 2016; 91(3):127-34. PubMed ID: 27362767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
    Trillet-Lenoir V; Chapuis F; Touzet S; Barbier JY; Freyer G; Gaudin JL; Lombard-Bohas C; Valette PJ; Lledo G; Gouttebel MC; Boyer JD; Chassignol L; Hamon H; Claudel-Bonvoisin S; Leprince E; Amoyal P; Glehen O; Darnand P; Heilmann MO; Bleuse JP
    Clin Oncol (R Coll Radiol); 2004 May; 16(3):196-203. PubMed ID: 15191007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy.
    Mao J; Du P; Yang HT; Hu H; Wang SY; Wu X; Cheng ZB
    Medicine (Baltimore); 2020 Apr; 99(14):e19420. PubMed ID: 32243362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
    Marks EI; Brennan M; El-Deiry WS
    Cancer Biol Ther; 2015; 16(8):1136-9. PubMed ID: 26047368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
    Iwanicki-Caron I; Di Fiore F; Roque I; Astruc E; Stetiu M; Duclos A; Tougeron D; Saillard S; Thureau S; Benichou J; Paillot B; Basuyau JP; Michel P
    J Clin Oncol; 2008 Aug; 26(22):3681-6. PubMed ID: 18669452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
    Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
    Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.